The Princess Margaret Radiation Medicine program has demonstrated strength and expertise in diverse research areas, including molecular radiation biology, radiation physics and imaging, education, outcome studies and clinical trials, and health services and epidemiology.

The basic goal of our laboratory research is to understand the cellular and molecular determinants of radiosensitivity in tumours and normal tissues with a long-term objective of bringing these innovations into the clinical setting. Through our affiliation with the University of Toronto’s Department of Radiation Oncology [opens in new window], where many of our staff are faculty members, we collaborate with other local, national and international cancer centres, such as the Odette Cancer Centre and the Ontario Institute for Cancer Research.

As part of the largest cancer centre in Canada, our internationally recognized team of researchers have access to large patient numbers presenting rare and complex cases and a range of clinical technologies at the cutting edge of radiation medicine, such as volumetric modulated arc therapy, MR-guided radiation therapy and MR interventional simulation.

Our researchers also have access to one of the leading cancer research facilities in the world through the Princess Margaret’s research arm [opens in new window], which is equipped with state-of-the-art tools in biobanking, genomics, proteomics, bioinformatics and other innovations that are moving findings “from the bench to the bedside and back to the bench.”

Our Strategic Plan identifies four interconnected themes that guides research priorities towards achieving our vision of "Precision Radiation Medicine. Personalized Care. Global Impact."

  1. Targeting cancer more precisely through innovation in MR-guided technologies and proton therapy
  2. Adapting radiation therapy informed by tumour morphological, micro-environmental and genomics features
  3. Enhancing patient and survivor health by better understanding the needs of our patients during and after treatment, measuring outcomes in a more relevant manner, managing long-term treatment side effects more effectively, and mitigating toxicity through tissue regeneration
  4. Learning from all of our patients by assembling comprehensive clinical, biological, dosimetric and outcomes 'big data' repositories to support research and innovation

Read our strategic plan [PDF, opens in new window] »



For more information about RMP's research programs, please contact Dr. Michael Milosevic.


Learn More
Last reviewed: 2/7/2018
Last modified: 2/8/2018 8:28 AM